MI-389 - ≥99% , CAS No.2222635-92-7

CAS: 2222635-92-7 Cat. No.: M1449817 Formula: C₃₅H₃₅FN₆O₆ Molecular Weight: 654.69

GRADE & PURITY ≥99%

Storage

Store at 2-8°C,Argon charged

Shipped In

Wet ice

Overview

MI-389 is a PROTAC translation termination factor GSPT1 degrader. MI-389 disrupts a target that is a shared dependency in different AML and ALL cell lines, and that MI-389 action is dependent on the CRL4 CRBN E3 ligase.

Specifications

Specifications & Purity

≥99%

Storage

Store at 2-8°C,Argon charged

Shipped In

Wet ice

This product requires cold chain shipping. Ground and other economy services are not available.

Purity

≥99%

Names and Identifiers

• Molecular Weight: 654.69

Application Protocols

Item-specific facts (from Product Data)

• No tested applications or validated protocols are provided for MI-389.

General small-molecule screening protocol (literature/general, example)

• Stock: prepare a 10–50 mM solution in anhydrous DMSO. Filter if particulates remain. Aliquot into low-bind tubes; store at 2–8°C or frozen per stability data (not provided here).
• Plate setup: dispense serial dilutions (e.g., 10-point 1:3 series) into assay plates to achieve desired final top concentration with ≤1% DMSO.
• Assay: add target-containing reagent/cells according to your assay SOP. Incubate for the required time (validated for the assay system).
• Readout: measure signal (e.g., fluorescence, luminescence, absorbance, activity units). Include vehicle controls and positive/negative controls.
• Analysis: fit concentration–response curves (four-parameter logistic). Flag outliers, check for edge effects, and confirm replicate consistency. Follow up with orthogonal confirmation.

Note: Adjust solvent percentages, incubation times, and detection methods to your specific assay. This guidance is general and not item-specific.

Biological Roles

Item-specific facts (from Product Data)

• No target, pathway, or mechanism information is provided for MI-389.

General guidance (literature/general)

• As a member of a small-molecule/compound library, MI-389 may be evaluated in diverse biological assays to probe potential modulation of enzymes, receptors, transporters, or signaling nodes. Without a disclosed structure or annotated target, any biological role is undetermined and should be established experimentally.
• Recommended approach: begin with primary screening (biochemical or phenotypic), followed by secondary confirmations and counterscreens to identify off-target interference (e.g., PAINS filters, redox activity, aggregation). Complement activity data with basic ADME profiling (stability, permeability, protein binding) as appropriate for your research.
• If literature exists for CAS 2222635-92-7, align experimental design to reported modalities (e.g., enzyme class, binding site) and replicate key controls. Absent literature, treat MI-389 as an unannotated chemical probe candidate and apply rigorous validation before deriving mechanistic conclusions.

Buffer Applications

Applicability

• MI-389 is not a buffering reagent. However, it is commonly handled in buffered systems during biological testing.

General guidance for buffer use with small molecules (literature/general)

• Stock preparation: dissolve in DMSO (or other suitable solvent), then dilute into assay buffer (e.g., PBS, HEPES, Tris) with thorough mixing to avoid precipitation. Keep final organic solvent below the assay’s tolerated limit (often 0.1–1% v/v).
• pH considerations: if the compound contains ionizable groups (unknown here), solubility can be pH-dependent. Conduct small pH/solubility screens (e.g., pH 6–8) to select a compatible buffer.
• Additives: 0.01–0.05% nonionic surfactant (e.g., Tween-20) can reduce nonspecific binding and aggregation in some biochemical assays; confirm compatibility with targets and readouts.
• Filtration: if particulate is observed after dilution, pass through a low-protein-binding 0.22 µm filter, recognizing potential analyte loss due to adsorption. Validate recovery.

Green Alternatives

Context for this item

• MI-389 is supplied as a research small molecule; no synthesis route or solvent-of-use is specified. Green considerations therefore focus on handling, formulation, and analytical workflows rather than process chemistry.

Practical greener choices (literature/general)

• Minimize DMSO usage by preparing the highest feasible stock concentration within solubility limits; reduces total organic solvent introduction to assays and waste streams.
• Prefer ethanol or aqueous cosolvent systems when compatible with assay biology, recognizing trade-offs in solubility and volatility.
• For chromatography, consider water–acetonitrile gradients rather than water–methanol where appropriate energy/waste balances and detector compatibility favor ACN; recover and recycle solvents when possible.
• Use microscale assays (low-volume plates, miniaturized analytics) to cut solvent consumption and waste generation.

Balanced trade-offs (literature/general)

• DMSO: excellent solvency but contributes to organic waste; hygroscopic—can introduce water into systems.
• Ethanol: bio-based and readily biodegradable; may have higher volatility and biological effects at equivalent percentages.
• Aqueous additives (cyclodextrins, surfactants): can reduce organic solvent dependency but introduce additional components that may affect assay readouts—validate thoroughly.

Pharmaceutical Uses

Item-specific facts (from Product Data)

• This product is for research use only and is not intended for human or veterinary use. No pharmacopeial status, excipient role, or formulation designation is provided.

General, non-clinical context (literature/general)

• Compounds like MI-389 may be employed as reference materials or test articles in preclinical research workflows (e.g., in vitro pharmacology, mechanistic studies). Any use in regulated studies should be supported by appropriate qualification of identity, purity, and stability.
• Formulation experiments (e.g., solubility screening, vehicle optimization) can be performed to understand compatibility with candidate delivery systems for research models; however, no clinical or therapeutic claims are applicable or implied for this item.

Physical Properties

Item-specific facts (from Product Data)

• Physical state/appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point (MP): Not specified for this item; refer to CoA/Spec Sheet.
• Boiling point (BP): Not specified for this item; refer to CoA/Spec Sheet.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet.
• LogP, pKa, refractive index: Not specified for this item; refer to CoA/Spec Sheet.

General handling properties (literature/general)

• Screening compounds are commonly dissolved for use as concentrated stocks in anhydrous DMSO, DMF, ethanol, or mixed solvent systems. Actual solubility is structure-dependent—perform a small-scale solubility screen to confirm.
• For aqueous work, typical strategies include cosolvent dilution (final DMSO 0.1–1% v/v), pH adjustment when ionizable functionality is present, or use of cyclodextrins/surfactants (if compatible with the assay). Validate against your assay’s tolerance.
• Hygroscopicity and air/oxidation sensitivity are unknown for this item. The storage guidance (2–8°C, Argon charged) suggests minimizing exposure to air/moisture; handle accordingly until specifications are confirmed.

Quality & Grades

Item-specific facts (from Product Data)

• Grade/purity: Not specified for this item; refer to CoA/Spec Sheet.
• Research use note: For research use only.

Guidance on grade interpretation (literature/general)

• In the absence of a stated grade (e.g., ≥98% HPLC, bioactive screening grade), rely on the Certificate of Analysis (CoA) for: assay method (HPLC/UPLC/GC), purity %, residual solvents, and identity verification (NMR, MS, HRMS as applicable).
• For screening applications, low UV-background and well-defined chromatographic purity are preferred to avoid assay artifacts. If LC–MS trace shows multiple components, consider additional purification or define acceptance criteria appropriate to your study.
• If a stabilizer is present in some lots, it will be disclosed on the CoA/label. Stabilizers can influence bioassay results; include matched vehicle controls.
• Batch-to-batch comparability: verify retention time and impurity profile against prior lots when used in ongoing SAR or mechanistic studies.
• Documentation: Ensure the CoA and SDS correspond to the received lot number before use in regulated research workflows.

Reaction & Applications

Item-specific facts (from Product Data)

• Manufacturer applications: Not specified beyond inclusion in a small-molecule/compound library category.

Research uses (literature/general, non-clinical)

• Screening/phenotypic assays: Employed as a test article in high-throughput or targeted biochemical/cell-based assays to explore activity profiles and generate preliminary SAR hypotheses.
• Tool-compound workflows: Used in dose–response experiments, time-course studies, and mechanism-of-action exploration when literature or internal data provide a hypothesized target. Include appropriate vehicle and inactive control arms.
• Orthogonal confirmation: Validate observed activities using alternative assay formats (e.g., enzymatic vs biophysical binding) to de-risk artifacts from aggregation, fluorescence interference, or redox cycling.
• Analytical characterization: Prior to biological testing, confirm lot identity and purity by LC–MS/NMR; monitor stability in assay media (time zero vs end-point) to ensure exposure consistency.

Practical tips (literature/general)

• Prepare single-use aliquots to minimize freeze–thaw and moisture uptake.
• Use low-bind plastics or silanized glass to mitigate adsorption losses, especially at sub-micromolar concentrations.
• Track compound plate maps and plate age; adsorption/evaporation can bias edge wells. Seal plates and limit dwell time at ambient conditions.

Reaction Conditions

Applicability

• This item is not supplied or described as a reagent or catalyst, and no reaction condition data are provided. Therefore, standard synthetic reaction conditions are not applicable.

General guidance (literature/general)

• For any contemplated chemical modification of MI-389 (e.g., prodrug or probe synthesis), determine functional groups by analytical characterization first, then select mild, chemoselective transformations to preserve the parent scaffold. Control temperature, exclude moisture/air if required, and monitor by LC–MS.
• Absent structural data, no typical temperatures, catalysts, or yields can be recommended for this specific item.

Safety & Handling

Item-specific facts (from Product Data)

• GHS classification: Not specified for this item; refer to SDS.
• Signal word: Not specified for this item; refer to SDS.
• Hazard (H) statements: Not specified for this item; refer to SDS.
• Pictograms: Not specified for this item; refer to SDS.
• Storage conditions: Store at 2–8°C, Argon charged; shipped on wet ice.

General safety guidance (literature/general)

• Use standard laboratory PPE: lab coat, safety glasses, and appropriate chemical-resistant gloves. Work in a fume hood to avoid inhalation of dusts/aerosols.
• Avoid contact with skin and eyes; prevent ingestion and inhalation. Wash thoroughly after handling.
• Given the inert-atmosphere storage, minimize exposure to air and moisture during use. Reseal under inert gas promptly after dispensing.
• Incompatibilities (general): strong oxidizers/reductants, strong acids/bases, and reactive metals may pose risks depending on structure. Keep away from ignition sources until flammability is known. Do not heat to decomposition.
• First aid (overview): if inhaled—move to fresh air; if on skin—wash with soap/water; if in eyes—rinse cautiously with water for several minutes; if ingested—rinse mouth. Seek medical attention in all cases. Defer to the SDS for authoritative instructions.
• Spill and disposal: Contain small spills with inert absorbents; collect in compatible waste containers. Dispose of according to institutional and local regulations.

Solvent Selection

Item-specific facts (from Product Data)

• No solvent preferences or solubility data are specified for this item; refer to CoA/Spec Sheet.

General solvent guidance for small-molecule screening (literature/general)

• Primary stock solvent: anhydrous DMSO is the default for many drug-like molecules due to high solvating power and assay compatibility at low final %.
• Alternative solvents: DMF or ethanol can be used when DMSO solubility is limited and assay systems tolerate them; acetonitrile is suitable for analytical dilutions.
• Aqueous work: dilute DMSO stocks into buffered saline or assay buffer with vigorous mixing. Keep final DMSO in the range tolerated by your system (often 0.1–1% v/v). Consider surfactants (e.g., 0.01–0.05% Tween-20) to reduce adsorption, if compatible.
• Insolubility/cloudiness: warm gently (≤37°C), sonicate briefly, or adjust concentration. Avoid strong base/acid unless the compound is known to be stable.

Small comparison (literature/general)

• DMSO: highest solvency; widely compatible; hygroscopic; can affect some enzyme/cell assays at >1%.
• Ethanol: good solvency; volatile; higher cytotoxicity at comparable % vs DMSO in some systems.
• DMF: strong solvency; less volatile; may be less tolerated biologically—validate carefully.

Storage & Reconstitution

Item-specific facts (from Product Data)

• Storage conditions: Store at 2–8°C, Argon charged.
• Shipping: Shipped on wet ice.
• Appearance: Not specified for this item; refer to CoA/Spec Sheet.

General guidance (literature/general)

• Inert-atmosphere handling: Open vials in a dry environment; purge headspace with argon or nitrogen after use. Cap tightly to limit air and moisture ingress.
• Reconstitution: If solid—dissolve initially in dry DMSO or another appropriate solvent to prepare a concentrated stock; if liquid—verify concentration and consider direct aliquoting. Because solubility is not specified, perform a small-scale solubility check.
• Aliquoting: Prepare single-use aliquots to avoid repeated freeze–thaw and moisture uptake. Use low-bind vials to minimize adsorption, especially at low concentrations.
• Short-term storage: 2–8°C under inert gas as indicated. Protect from light if the compound is chromophoric (unknown here); amber vials are prudent until data are available.
• Long-term storage: If stability permits (consult CoA/SDS), freezing at −20°C or −80°C can extend shelf life; avoid frost-free freezers. Document any observed precipitation/crystallization upon cooling and redissolve with gentle warming/sonication.

Always refer to the lot-specific CoA and SDS for definitive storage, stability, and reconstitution instructions.

Structure & Identity

Item-specific facts (from Product Data)

• SKU: M1449817
• Product name: MI-389
• CAS: 2222635-92-7
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.

General notes for identity (literature/general)

• MI-389 is cataloged under small molecules/compound libraries. In the absence of a disclosed structure, it should be treated as a research screening compound. Confirm identity and purity using the item’s CoA/SDS or by orthogonal analytical methods (e.g., LC–MS, 1H NMR) as required by your QA/QC procedures.

2D structural description (general guidance)

• Structural features (rings, heteroatoms, stereocenters) are not disclosed in the Product Data. If structural elucidation is necessary, consult the supplier’s full specification or published literature associated with CAS 2222635-92-7.

Synthetic Utility

Applicability

• MI-389 is supplied as a finished small molecule for screening. Without a disclosed structure or functional group information, it is not positioned as a synthetic building block or reagent.

General remarks (literature/general)

• If structural information becomes available and reactive handles are present (e.g., aryl halides, amines, acids), analog generation or probe derivatization (e.g., biotin/fluorophore tagging via linkers) could be envisioned for chemical biology. Such modifications should be guided by SAR to preserve activity.
• For analytical derivatization (e.g., to create immobilized ligands for pull-downs), confirm stability of the core scaffold and choose chemoselective coupling strategies compatible with the compound’s functional groups.

Target Specificity

Item-specific facts (from Product Data)

• No target, selectivity profile, or binding data are provided for MI-389.

General guidance (literature/general)

• Establish putative specificity using a tiered approach: primary activity assay; orthogonal assay (biophysical/enzymatic); selectivity panel against related targets; and off-target liability assessment (e.g., counterscreens for frequent hitters, redox/fluorescence interference).
• Report EC50/IC50/Kd values with assay conditions and error estimates. Confirm that observed effects are not due to aggregation (test with detergent), reactivity (thiol traps), or colloidal behavior (DLS).
• If using MI-389 as a tool compound, include structurally related inactive analogs where possible to strengthen causal inference.